Erratum to: Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: Integrated results from three randomized, double-blind studies of denosumab and zoledronic acid (Support Care Cancer (2013) 21, (3497-3507) DOI: 10.1007/s00520-013-1932-2);Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: Integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

Supportive Care in Cancer

Volumn 21, Issue 12, 2013, Pages 3497-3507

  Von Moos, Roger ^a   Body, Jean Jacques ^b   Egerdie, Blair ^c   Stopeck, Alison ^d   Brown, Janet E ^e   Damyanov, Danail ^f   Fallowfield, Lesley J ^g   Marx, Gavin ^h   Cleeland, Charles S ⁱ   Patrick, Donald L ^j   Palazzo, Felipe G ^k   Qian, Yi ^l   Braun, Ada ^l   Chung, Karen ^l  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c Urology Associates Urologic Medical Research   (Canada)

^d UNIVERSITY OF ARIZONA   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f National Specialized Hospital for Active Treatment in Oncology   (Bulgaria)

^g UNIVERSITY OF SUSSEX   (United Kingdom)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k CAIPO   (Argentina)

^l AMGEN INC   (United States)

more..

Author keywords

Bone metastases; Denosumab; Pain; Solid tumours; Zoledronic acid

Indexed keywords

ANALGESIC AGENT; DENOSUMAB; NARCOTIC ANALGESIC AGENT; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; YOUNG ADULT;

EID: 84889093279     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2293-1     Document Type: Erratum

References (34)

1. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
2. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s
3. Dranitsaris G, Hatzimichael E (2012) Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer 20:1353-1360
4. van der Linden YM, Lok JJ, Steenland E, Martijn H, van Houwelingen H, Marijnen CA, Leer JW (2004) Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 59:528-537
5. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-596
6. Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985-1991
7. Janjan N (2001) Bone metastases: approaches to management. Semin Oncol 28:28-34
8. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 1.2013). National Comprehensive Cancer Network
9. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 1.2013). National Comprehensive Cancer Network
10. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer (Version 2.2013). National Comprehensive Cancer Network
11. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132-5139
12. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813-822
13. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132
14. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082-3092
15. 2012 Zometa® (zoledronic acid) Injection. Full prescribing information. Novartis Pharmaceuticals Corporation
16. Cleeland C (2009) The brief pain inventory user guide. The University of Texas MD. Anderson Cancer Center, Houston
17. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC (1996) Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 67:267-273
18. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
19. Chung KC, Barlev A, Braun A, Qian Y, Zagari M (2009) Development of the Analgesic Quantification Algorithm (AQA): a new scale to assess analgesic use [Poster]. Joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology
20. Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K (2011) Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol 9:72-78
21. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287-294
22. Webster K, Cella D, Yost K (2003) The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1:79
23. Goblirsch MJ, Zwolak PP, Clohisy DR (2006) Biology of bone cancer pain. Clin Cancer Res 12:6231s-6235s
24. Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, Nishisho T, Sakurai T, Hiraga T (2011) Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone 48:100-105
25. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O'Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528
26. Kaasa S, Apolone G, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Groenvold M, Fainsinger R, Jensen MP, Farrar JT, McQuay H, Rothrock NE, Cleary J, Deguines C, Caraceni A (2011) Expert conference on cancer pain assessment and classification - the need for international consensus: working proposals on international standards. BMJ Support Palliat Care 1:281-287
27. von Moos R, Strasser F, Gillessen S, Zaugg K (2008) Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 16:1105-1115
28. Milani B, Scholten W (2011) The World Medicines Situation 2011: Access to Controlled Medicines (apps.who.int/medicinedocs/documents/s18062en/s18062en. pdf). World Health Organization (WHO), Geneva
29. Gater A, Abetz-Webb L, Battersby C, Parasuraman B, McIntosh S, Nathan F, Piault EC (2011) Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes 9:88
30. Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 28:192-211
31. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869-876
32. Saad F (2005) Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4:31-37
33. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869-1876
34. Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986-989